AmoyDx plans to increase its investment in upstream gene sequencing company SaiLu Medical by 50 million yuan

According to the Zhitong Finance APP, AmoyDx (300685.SZ) announced that on October 9, 2025, the company signed a Series B capital increase agreement with Shenzhen Sailu Medical Technology Co., Ltd. (hereinafter referred to as "Sailu Medical" or "the target company") and its existing shareholders. AmoyDx will increase its capital in Sailu Medical by 50 million yuan in cash, of which 55,701 yuan will be used as the new registered capital of Sailu Medical, and the remaining amount will be included in Sailu Medical's capital reserve. After this capital increase, AmoyDx will hold 2.3810% of the equity in Sailu Medical. As an upstream enterprise in the gene sequencing industry chain, Sailu Medical operates in a highly technology-intensive industry with significant R&D barriers. Sailu Medical has successfully built a self-controllable sequencing technology platform and possesses complete R&D and production capabilities for gene sequencing instruments and related reagents. Its SalusPro gene sequencer was approved for a Class III medical device registration certificate by the state in January 2025. Currently, the country continues to promote the self-control and import substitution of high-end medical equipment, providing strategic development opportunities for domestic sequencing platform companies with core technologies. This capital increase in Sailu Medical is a key strategic deployment for the company, based on the development trends in the gene testing industry and strengthening the synergy of the industrial chain. Against the backdrop of the accelerating process of domestic substitution in gene sequencing, this cooperation will fully leverage Sailu Medical's core advantages in sequencing platforms, forming a strong complement with the company's technological accumulation and product strength in the field of tumor gene testing. This will not only help enhance the company's overall competitiveness in the industry but also promote the integration of upstream and downstream resources, building a more self-controllable and collaboratively developed industrial ecosystem. This move will further accelerate the innovation and clinical transformation of cutting-edge technologies, providing patients with more precise and accessible gene testing solutions, and continuously consolidating the company's leading position in the field of precision medicine for tumors